N. Le

发表

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

E. Van Cutsem, J. Tabernero, L. Paz-Ares, 2014, Clinical Cancer Research.

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

J. Sosman, A. Ribas, P. Hwu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, N. Le, 2012, The Lancet. Oncology.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

K. Flaherty, R. Kurzrock, N. Le, 2014 .

Regulating regulatory T cells

N. Le, N. Chao, Ngocdiep Le, 2007, Bone Marrow Transplantation.

Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting.

N. Le, N. Chao, B. J. Chen, 2005, Cytotherapy.

396 NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation

Omar H. Butt, N. Le, G. Dunn, 2021, Journal for ImmunoTherapy of Cancer.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2014, European journal of cancer.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.

J. Tabernero, R. Kurzrock, A. Stathis, 2012 .

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

R. Herbst, E. Rasmussen, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

I. Flinn, S. de Vos, A. Pettitt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.

Suzanne F. Jones, A. Tolcher, N. Le, 2013, European Journal of Cancer.

Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse.

J. Whitesides, N. Le, N. Chao, 2007, Blood.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

U. Jaeger, J. Delgado, S. Stilgenbauer, 2018, Blood.

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, C. Takimoto, 2010, Clinical Cancer Research.

404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

Melissa L. Johnson, N. Le, A. Naing, 2021, Journal for ImmunoTherapy of Cancer.

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.

Suzanne F. Jones, A. Tolcher, N. Le, 2011 .

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015 .

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2013 .

Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).

Sung-Bae Kim, Y. Im, N. Le, 2020 .

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

R. Herbst, E. Rasmussen, R. Kurzrock, 2009, Journal of Clinical Oncology.